| Jonathan Bennion, MD | |
|
10 Coburg Rd Ste 201, Eugene, OR 97401-7487 | |
| (541) 485-3636 | |
| (541) 344-4305 |
| Full Name | Jonathan Bennion |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 12 Years |
| Location | 10 Coburg Rd Ste 201, Eugene, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639439862 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | MD182366 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bay Area Hospital | Coos bay, OR | Hospital |
| Mercy Medical Center | Roseburg, OR | Hospital |
| Peace Harbor Medical Center | Florence, OR | Hospital |
| Peacehealth Cottage Grove Community Medical Center | Cottage grove, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Praxis Health Pc | 8325941446 | 167 |
News Archive
Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.
Only 1 in 10 people who need palliative care - that is medical care to relieve the pain, symptoms and stress of serious illness - is currently receiving it. This unmet need is mapped for the first time in the "Global atlas of palliative care at the end of life", published jointly by the WHO and the Worldwide Palliative Care Alliance.
National Institutes of Health (NIH) scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Florida Hospital, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and Takeda Pharmaceutical Company Limited (Takeda)(TSE: 4502), announced today that they have signed a research agreement to form a collaboration to discover and evaluate new therapeutic approaches to obesity, a growing worldwide health problem. The partnership aligns complementary strengths in biomedical research, clinical research and drug development to identify and validate obesity- related biomarkers and new peripheral molecular targets of mutual interest.
› Verified 2 days ago
| Entity Name | Praxis Health Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821068164 PECOS PAC ID: 8325941446 Enrollment ID: O20040128000241 |
News Archive
Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.
Only 1 in 10 people who need palliative care - that is medical care to relieve the pain, symptoms and stress of serious illness - is currently receiving it. This unmet need is mapped for the first time in the "Global atlas of palliative care at the end of life", published jointly by the WHO and the Worldwide Palliative Care Alliance.
National Institutes of Health (NIH) scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Florida Hospital, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and Takeda Pharmaceutical Company Limited (Takeda)(TSE: 4502), announced today that they have signed a research agreement to form a collaboration to discover and evaluate new therapeutic approaches to obesity, a growing worldwide health problem. The partnership aligns complementary strengths in biomedical research, clinical research and drug development to identify and validate obesity- related biomarkers and new peripheral molecular targets of mutual interest.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Bennion, MD 10 Coburg Rd Ste 201, Eugene, OR 97401-7487 Ph: (310) 922-8008 | Jonathan Bennion, MD 10 Coburg Rd Ste 201, Eugene, OR 97401-7487 Ph: (541) 485-3636 |
News Archive
Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.
Only 1 in 10 people who need palliative care - that is medical care to relieve the pain, symptoms and stress of serious illness - is currently receiving it. This unmet need is mapped for the first time in the "Global atlas of palliative care at the end of life", published jointly by the WHO and the Worldwide Palliative Care Alliance.
National Institutes of Health (NIH) scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Florida Hospital, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and Takeda Pharmaceutical Company Limited (Takeda)(TSE: 4502), announced today that they have signed a research agreement to form a collaboration to discover and evaluate new therapeutic approaches to obesity, a growing worldwide health problem. The partnership aligns complementary strengths in biomedical research, clinical research and drug development to identify and validate obesity- related biomarkers and new peripheral molecular targets of mutual interest.
› Verified 2 days ago
Richard Romm, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 677 E 12th Ave, Suite N400, Eugene, OR 97401 Phone: 541-484-4332 Fax: 541-302-0786 | |
William E Wilkins Jr., M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 330 S Garden Way Ste 350, Eugene, OR 97401 Phone: 541-746-6816 | |
Dr. Norman Paul Hudson, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2479 Oakmont Way, Eugene, OR 97401 Phone: 541-484-0195 Fax: 541-343-6317 | |
Kirk Douglas Jacobson, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1488 Oak St, Eugene, OR 97401 Phone: 541-431-0000 Fax: 541-344-6176 | |
Matthew B. Walter, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3125 Chad Dr Ste 100, Eugene, OR 97408 Phone: 541-687-1712 Fax: 541-687-7943 | |
Sarah Cassell, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 132 E Broadway Ste 830, Eugene, OR 97401 Phone: 541-687-0816 Fax: 541-687-1086 | |
Dr. Klarissa N Beller, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1200 Hilyard St Ste 520a, Eugene, OR 97401 Phone: 541-687-6041 Fax: 541-687-6009 |